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Background. Alzheimer’s disease (AD) is a devastating neurological disorder and the main cause of dementia in the elderly
population worldwide. Adult neurogenesis appears to be upregulated very early in AD pathogenesis in response to some speciﬁc
aggregates of beta-amyloid (Aβ) peptides, exhausting the neuronal stem cell pools in the brain. Previously, we characterized a
conservednonprotein-codingantisensetranscriptforβ-secretase-1(BACE1),acriticalenzymeinADpathophysiology.Weshowed
that the BACE1-antisense transcript (BACE1-AS) is markedly upregulated in brain samples from AD patients and promotes the
stability of the (sense) BACE1 transcript. In the current paper, we examine the relationship between BACE1, BACE1-AS, adult
neurogenesis markers, and amyloid plaque formation in amyloid precursor protein (APP) transgenic mice (Tg-19959) of various
ages. Results. Consistent with previous publications in other APP overexpressing mouse models, we found adult neurogenesis
markers to be noticeably upregulated in Tg-19959 mice very early in the development of the disease. Knockdown of either one of
BACE1 or BACE1-AS transcripts by continuous infusion of locked nucleic acid- (LNA-) modiﬁed siRNAs into the third ventricle
over the period of two weeks caused concordant downregulation of both transcripts in Tg-19959 mice. Downregulation of BACE1
mRNA was followed by reduction of BACE1 protein and insoluble Aβ. Modulation of BACE1 and BACE1-AS transcripts also
altered oligomeric Aβ aggregation pattern, which was in turn associated with an increase in neurogenesis markers at the RNA and
protein level. Conclusion. We found alterations in the RNA and protein concentrations of several adult neurogenesis markers, as
well as non-protein-coding BACE1-AS transcripts, in parallel with the course of β-amyloid synthesis and aggregation in the brain
of Tg15999 mice. In addition, by knocking down BACE1 or BACE1-AS (thereby reducing Aβ production and plaque deposition),
we were able to modulate expression of these neurogenesis markers. Our ﬁndings suggest a distortion of adult neurogenesis that is
associated with Aβ production very early in amyloid pathogenesis. We believe that these alterations, at the molecular level, could
prove useful as novel therapeutic targets and/or as early biomarkers of AD.
1.Background
Alzheimer’s disease is the most common form of dementia
characterized by progressive impairment of cognition and
short-termmemory loss. The deposition of Aβ 1–42 in senile
plaques is an established feature of AD neuropathology.
Diﬀerent species of Aβ have been shown to have toxic
eﬀects in vitro and in vivo; however, controversy still exists
about whether the amyloidogenic pathway is the initiating
mechanism for AD pathogenesis, or a mere consequence of
other pathogenic events. Several human amyloid precursor
protein(APP)mutations,aswellasmutationsinPresenilin-1
and Presenilin-2 were identiﬁed as genetic causes of familial
AD [1]( Figure 1). These mutations related to familial and2 International Journal of Alzheimer’s Disease
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Figure 1: Amyloid precursor protein (APP)cleavage and mutation. The present diagram represent APP, a transmembrane protein precursor
of Aβ peptide, with the three principal cleavage site (β-secretase or BACE, α-secretase, and γ-secretase) and several known mutations.
early onset AD formed the basis for the amyloid cascade
hypothesis to explain the pathogenesis of AD. β-secretase
(BACE1) is the rate-limiting enzyme responsible for the
production of Aβ peptides. Oligomeric forms of Aβ 1–42 can
induce other components of AD pathophysiology, such as
mitochondrialdysfunction[2,3],Tauhyperphosphorylation
(Tauhypothesis)[4],NMDARendocytosis(channelhypoth-
esis), excessive calcium inﬂux (calcium hypothesis) [5, 6],
synaptic dysfunction [7], neuronal stress [8], apoptosis
(neurovascular hypothesis) [9], and aberrant neurogenesis
[10, 11]. Therefore, BACE1 seems to be a critical component
of many pathologic pathways, as its dysregulation can lead to
excessiveproductionofAβ 1–42,formationofoligomericAβ
species, and development of amyloid plaques.
Pluripotent neural stem cells (NSC) are present in the
embryonic as well as adult brain [12–16]. Neural stem
cells can be isolated from various parts of the brain and
expanded in vitro, in the presence of mitogenic factors suchInternational Journal of Alzheimer’s Disease 3
as epidermal growth factor (EGF) or basic ﬁbroblast growth
factor (bFGF) [17]. However, NSC remain quiescent, or are
able to diﬀerentiate only to glial cells, in most parts of the
adult nervous system with the exception of two regions,
deﬁnedasneurogenicniches,wherenewneuronsareactively
generated, in vivo. Neurogenic niches, comprising the sub-
ventricular zone (SVZ) and subgranular zone of the hip-
pocampus,containactivestemcellsthatdiﬀerentiatetowards
neurons in the postnatal mammalian brain throughout their
life under normal physiologic conditions [18, 19]. In the
neurogenic niches, NSC are able to self-renew, proliferate,
diﬀerentiate towards neurons, and incorporate into the
neuronal circuitry [20]. Some reports indicate age-related
decreases in adult neurogenesis that might be associated
with a decline in hippocampus-dependent learning [18, 19,
21–23]. As memory loss and impaired learning are two
of the most pronounced behavioural symptoms of AD, it
seems likely that changes in neurogenesis could play a role
in the progression of the disease. Increased neurogenesis
has been described in neuronal stem cells treated with
Aβ peptides in vitro [10], in animal models of AD [11]
and in AD patients [24]. Interestingly, in the J20 APP
transgenic mouse model of AD the observed in vivo eﬀect
of Aβ peptides on neurogenesis is mainly age dependent.
In J20 mice, hippocampal neurogenesis is greatly enhanced
at a young age, long before manifestation of any other
AD-related symptoms, and dramatically reduced in older
animals, when amyloid plaques are present and cognitive
impairment is apparent [11]. Therefore, adult neurogenesis
seems to correlate with the production of Aβ peptides and
the accumulation of speciﬁc aggregates of Aβ in the brain.
We sought to determine whether another mouse model of
AD (Tg-19959) exhibits alterations in adult hippocampal
neurogenesis markers and if so, to relate these changes with
the levels of Aβ production and aggregation. Lastly, sought
to determine whether we could modify these changes by
targeting non-protein-coding RNAs.
Non-protein-coding RNAs (ncRNAs) appear to play an
instrumental,butlargelyabandoned,roleinhumancomplex
disorders [25]. Natural antisense transcripts are a group of
regulatory RNAs, transcribed from the opposite strand of
other (sense) genes [26]. Antisense transcripts are mainly
n c R N A sa n dh a v eb e e nr e p o r t e dt or e g u l a t eg e n ee x p r e s s i o n ,
either positively or negatively, through various mechanisms
[27]. The discovery of BACE1 as the rate-limiting enzyme
in the production of Aβ peptides has made it a prime
therapeutic target for AD. Recently, we have identiﬁed
and characterized one sense-antisense pair, BACE1 and its
antisense partner BACE1-AS, and demonstrated a critical
role of this non-protein-coding natural antisense transcript
in AD [28]. BACE1-AS has the potential to participate in
an ncRNA network that serves to ﬁne-tune BACE1 protein
output in the nervous system.
In the current study, we investigated mechanisms behind
Aβ-induced hippocampal neurogenesis in the Tg-19959
model of AD. In particular, we investigated the extended
eﬀects of BACE1-AS transcripts on amyloid production,
aggregation and plaque formation and their eﬀects in adult
neurogenesis in vivo.
2. Results and Discussion
2.1. Neurogenesis over Time in Tg-19959 Mice. We assessed
adult neurogenesis in hippocampus at diﬀerent time points
throughout the life of Tg-19959 mice. We measured cell
proliferation (by Ki67 staining) in the dentate gyrus of
wildtype and Tg-19959 mice at diﬀerent ages and observed a
signiﬁcant increase in NSC proliferation in young Tg-19959
animals (5 weeks old), as compared to age-matched wildtype
mice (Figures 2(a) and 2(b)). This enhanced proliferation of
NSC persisted over time as the animals aged (Figure 2(c)).
We also quantiﬁed neural stem cell and progenitor markers
in these mice over time, both at the RNA and protein level
by RT-PCR and Western blot, respectively. Nestin is an
intermediateﬁlamentproteinusedasamarkerofpluripotent
neural progenitors. It is expressed in type 1 and 2 cells in
the adult hippocampus and it would represent the amount
of neural progenitors and early neuronal progenitors in
adult neurogenesis. Doublecortin (DCX) is a microtubule-
associated protein expressed in neuronal committed precur-
sor cells and immature neurons (type 2 and 3 cells) in the
adult hippocampus [29]. The quantiﬁcation of nestin and
doublecortin levels in the hippocampus indicated a signiﬁ-
cant increase of both markers in Tg-19959, as compared to
wild type mice both at the RNA (Figure 2(d))a n dp r o t e i n
level (Figure 2(e)). Increased levels of neurogenesis markers
were maintained over time as the animals aged. These data
are consistent with the increased proliferation observed by
Ki67 staining in the dentate gyrus and indicate that there is
an early and persistent enhancement of hippocampal neuro-
genesisinTg-19959miceversusage-matchedwildtypemice.
2.2. Aβ Accumulation over Time in Tg-19959 Mice. Tg-19959
mice exhibit detectable Aβ plaques as early as 2 months of
age and soluble Aβ peptides are detectable by 4 weeks of age
(Figure 3). Five regions of Tg-19959 mouse brain (prefrontal
cortex (PFC), hippocampus anterior (HPA), hippocampus
posterior (HPP), striatum (ST), and cerebellum (CB)) were
isolated at diﬀerent ages and the levels of Aβ 1–42 and Aβ
1–40 quantiﬁed by AlphaLISA. Transgenic mice showed an
age-dependent accumulation of soluble Aβ 1–40 and Aβ 1–
42 in all regions examined (Figures 3(a) and 3(b)). Western
blot analysis of hippocampal lysates from these mice showed
an age-dependent accumulation of soluble Aβ aggregates
(Figure 3(c)). Immunohistochemistry using 48G antibody,
show a time-dependent increase in insoluble deposits of Aβ
in hippocampus (Figures 3(d)–3(h)).
We hypothesized that speciﬁc soluble oligomeric Aβ
aggregates might be involved in enhancement of neuro-
genesis over time, as we explained in a previous review
[30]. Numerous reports have shown the important role
of oligomeric Aβ species in AD pathologic processes [31–
34]. In our studies, we show that Tg-19959 mice display
an age-dependent enrichment of oligomeric Aβ species
(Figure 3(c)). Our data show that compared to age-matched
wildtype mice, neurogenesis is greatlyincreasedin Tg-19959
mice as early as 5 weeks of age, and at all subsequent ages
examined. This increase in neurogenesis occurs in very early
ages, correlates with detectable levels of Aβ aggregates in4 International Journal of Alzheimer’s Disease
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Figure 2: Tg-19959 mice exhibit increased proliferation in the dentate gyrus at all ages. We measured Ki67, a marker of cell proliferation in
the dentate gyrus of wild type and Tg-19959 mice at diﬀerent ages. There is signiﬁcant increase in NSC proliferation in 5-week-old Tg-19959
mice (b) versus littermates wild type (a) that is maintained over time as animals aged (c). The markers of nestin (neural progenitor marker)
and doublecortin (DCX, neuronal progenitor marker) were also signiﬁcantly increased versus wild type in both mRNA (d) and protein (e)
levels in hippocampus at all ages.
the brain, and it precedes any cognitive deﬁcits in the mice,
suggesting a relationship between Aβ and neurogenesis.
These results also agree with our previous ﬁndings, where
we described that speciﬁc oligomeric Aβ species are able to
induce neurogenesis in vitro [10].
Consistently with our present results, in J20 APP over-
expressing mice, there is a signiﬁcant NSC proliferation in
3-month-old animals versus wild type animals. However,
the neurogenesis rate in J20 mice decreases below wild type
levels in older mice [11]. In Tg-19959 mice, we observed
that this increase in neurogenesis in younger animals is
more persistent and it extends to the aged animals. It has
been reported that diﬀerent aggregation states can play an
important role in the eﬀects of Aβ in cell death and/or
neurogenesis [10, 32]. In addition, we showed an increased
neurogenesis in Tg-19959 mice that is potentially related
to enrichment of particular oligomeric assemblies [30].
We hypothesize that the diﬀerences in Aβ production and
subsequent aggregation between both animal models could
explain these diﬀerences. For this reason, the possibility to
regulate Aβ production by manipulating BACE1 activity
could open many possibilities in the neurogenesis-AD ﬁeld.
2.3.Knock-downofBACE1-ASandBACE1TranscriptInVitro.
The modulation of BACE1 by ncRNAs could be a good
tool to modify Aβ production, its further aggregation, andInternational Journal of Alzheimer’s Disease 5
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Figure 3: β-Amyloid peptide accumulates with aging in Tg-19959 APP transgenic mice. The level of soluble Aβ 1–42 and Aβ 1–40 amyloid
peptides in prefrontal cortex (PFC), hippocampus anterior (HPA), hippocampus posterior (HPP), striatum (ST), and cerebellum (CB) at
diﬀerent ages, compared to wild type controls were quantiﬁed by AlphaLISA. Both Aβ 1–42 (a) and Aβ 1–40 (b) were gradually increased as
animals aged, in all regions studied. The Western blot of hippocampal samples at diﬀerent ages using the 48G antibody shows an increase
over time in speciﬁc aggregation of Aβ (c). Immunohistochemistry with the 4G8 antibody against Aβ at diﬀerent ages shows insoluble Aβ
deposits in Tg-19959 hippocampi as early as in 2-month-old animals. (d): 2m/o, (e); 6m/o, (f): 10m/o, (g): 13m/o, and (h): 26m/o. Green:
4G8. Blue: Hoechst.
its eﬀect in hippocampal adult neurogenesis. To assess the
regulatory eﬀects of BACE1-AS on BACE1 transcripts, we
designed LNA-modiﬁed oligos for knockdown of BACE1
and BACE1-AS transcripts. We also designed LNA-modiﬁed
oligos simultaneously targeting both BACE1 and BACE1-
AS transcripts, with equal nucleotide composition on both
sides. We learned from previously published work that the
two strands of an siRNA duplex are not equally eligible
for assembly into RNA-induced silencing complex (RISC)
[35]. Asymmetric stability of the 5  end of an siRNA duplex
determines the degree to which each strand participates in
the RNAi pathway. Therefore, we designed our siRNA tar-
geting the overlapping region between BACE1 and BACE1-
AS transcripts, with symmetric stability at both ends to6 International Journal of Alzheimer’s Disease
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Figure 4: Eﬀects of siLNA and sisiLNA in BACE1 and BACE1-AS RNA levels in vitro. To test the ability of siLNAs (a) and sisiLNAs (b) on
BACE1 and BACE1-AS, we performed a study in mouse neuroblastoma N2a cells in vitro. Selective targets against BACE1-AStranscript were
able to signiﬁcantly knockdown not only BACE1-AS but also BACE1, supporting the proposed concordant regulation of BACE1 mRNA by
BACE1-AS.
facilitate incorporation of both strands into RISC, resulting
in simultaneous knockdown of both BACE1 and BACE1-
AS transcripts. Additionally, we designed small internally
segmentedinterferingRNAs(sisiRNAs)[36]forbothBACE1
andBACE1-AS transcripts to be able to assess strand-speciﬁc
eﬀects of siRNA molecules. We examined LNA-modiﬁed
oligos in mouse neuroblastoma N2a cells. In line with our
previous ﬁndings [28], we found that selective targeting of
the BACE1-AS transcript resulted in a statistically signiﬁcant
knockdown of not only the targeted BACE1-AS transcript,
but also BACE1 mRNA (Figures 4(a) and 4(b)). Overlap-
ping LNA modiﬁed siRNA reduced BACE1 and BACE1-
AS transcripts, simultaneously. Strand-selective knockdown
of BACE1-AS transcript, using sisiRNAs reduced the level
of both BACE1 and BACE1-AS transcript (Figure 4(b)).
These data conﬁrm the proposed concordant regulation of
BACE1mRNAbynon-protein-codingBACE1-AStranscript,
in which the antisense transcripts change the level of the
sense RNA or the corresponding protein abundance in a
positive way.
2.4. Knockdown of BACE1-AS Reduces BACE1 Levels In
Vivo. Having already demonstrated a role for BACE1-AS in
regulatingBACE1functioninvitro,wenextassessedwhether
LNA-modiﬁed siRNAs show similar regulatory eﬀects in
vivo in mouse brain. We surgically implanted osmotic
minipumps in the third ventricle of Tg-19959 mice and
infused LNA-modiﬁed siRNA (1mM) targeted to BACE1,
BACE1-AS, the overlapping region between BACE1 and
BACE1-AS transcripts, or an inert LNA-modiﬁed siRNA, as
control (ﬁve animals per group). Continuous infusion of
LNA modiﬁed siRNAs, over 14 days, resulted in reduced
BACE1 mRNA levels across forebrain regions located adja-
cent to the third ventricle (Figure 5). Of the three siRNAs
used, the overlapping siRNAs were most potently able to
reduce BACE1 mRNA levels (approximately 60% knock-
down of BACE1 in each of the brain regions examined),
suggesting simultaneous targeting of both transcripts as
the most potent therapeutic approach for reduction of
BACE1, in vivo (Figures 5(a)–5(c)). Similar eﬀect was found
in BACE1 protein (Figure 5(d)). Surprisingly, we observed
only a minimal knockdown of BACE1 after BACE1 siRNA
infusion. This may be due to either a blockage of the osmotic
mini-pump tubing, or due to an insuﬃcient dose of siRNA
since we have used a relatively low concentration of siRNA
for these experiments (1mM).
2.5. Assessment of Aβ Aggregation Species after BACE1
and BACE1-AS Knockdown. The ability to modulate Aβ
production and its further aggregation could open new
possibilities for AD therapeutics in relation to neurogenesis.
We attempted to investigate whether we could alter Aβ
accumulation by using siLNAs to BACE1, BACE1-AS, and
the overlap region. Our initial in vitro experiments showed
that siLNA targeting the BACE1 sense/antisense overlap
region gave the greatest knockdown of both BACE1 and
BACE1-AS mRNA, supporting our previous publication
showing concordant regulation of BACE1 and BACE1-AS
(Figure 4)[ 28]. Following 14 days of in vivo treatment with
BACE1 sense/antisense overlap siLNA on Tg-19959 mice,
we observed knockdown of BACE1 sense and antisense
transcripts in all brain regions examined, conﬁrming our in
vitro data (Figure 5).
In order to determine whether the knockdown of BACE1
or BACE1-AS can alter the accumulation of particular
oligomeric aggregates of Aβ, we examined Aβ aggregation in
the hippocampus of mice after LNA-modiﬁed siRNA treat-
ments. We homogenized mouse hippocampi after 14 daysInternational Journal of Alzheimer’s Disease 7
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Figure 5: Eﬀects of siLNA in BACE1 and BACE1-AS RNAs levels in vivo. To test the ability of siLNAs to aﬀect BACE1 and BACE1-AS in vivo,
we inserted a minipump as explained with overlap siLNA (a), BACE1-AS siLNA (b), and BACE1 siLNA (c) during two weeks. LNA-modiﬁed
siRNAs reduced BACE1 mRNA levels in approximately 60% in each of the brain regions examined. In hippocampus, the protein levels of
BACE1 were also clearly reduced (d, duplicates).
of LNA-modiﬁed siRNA infusion and measured Aβ 1–40
and 1–42, by alphaLISA. We found small in non-signiﬁcant
changes in the total amount of soluble Aβ (Figures 6(a)
and 6(b)); however, we observed a signiﬁcant reduction of
insoluble (guanidine extracted) Aβ 1–40 and Aβ 1–42 levels
after BACE-1-AS infusion (Figures 6(c) and 6(d)). Separa-
tion of Aβ species by Western blot revealed that all three
LNA-modiﬁedsiRNAtreatments(BACE1siLNA,BACE1-AS
siLNA, and overlap siLNA) resulted in a signiﬁcant change
in Aβ aggregation pattern in mouse brain (Figure 6(e)).
Several reports show the relation and equilibrium between
soluble and insoluble levels of Aβ [37]. We did not detect
signiﬁcant changes in the total amount of soluble Aβ with
the siRNA treatments; however, we found reduced levels of
insoluble Aβ 1–40 and Aβ 1–42 (an indicator of plaque
formation) in the brain regions examined (Figures 6(c) and
6(d)).Ourdatasupportourhypothesisthatthemodiﬁcation
of Aβ production is able to change the total amount of
Aβ production by changing the pattern of aggregation. We
hypothesize that a slower pace in Aβ production determines
a slower aggregation that results in less accumulation in
insoluble plaques.
Next, we assessed the eﬀects of BACE1 and BACE1-
AS reduction on DCX mRNA levels. We measured this
marker of neuronal progenitors in the hippocampus after
LNA-modiﬁed siRNA treatments. We found increased DCX
mRNA levels in hippocampus (Figure 7(a)). We next mea-
sured the level of DCX protein in these same mice and8 International Journal of Alzheimer’s Disease
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Figure 6: Eﬀects of siLNA in for BACE1, BACE1-AS and overlap region in Aβ formation and aggregation. The infusion of siLNA for
two weeks did not change the total amount of soluble Aβ in hippocampus (a), however, it did change the aggregation pattern (b). The
measurement of insoluble Aβ (plaque aggregates) by guanidine extraction showed a signiﬁcant decrease with BACE1-AS treatment (c-d).
observed an enhancement of DCX protein expression
(Figure 7(b)). These data provide further evidence that
particular Aβ assemblies may be responsible for driving neu-
rogenesis in Tg-19959 mice, consistently with our previous
reports in J20 mice [11]. We propose that the alteration of
BACE1 protein levels changes the pace of Aβ production and
ulterior aggregation state in APP overexpressing mice. This
phenomenon would enrich the hippocampus in the soluble
oligomers of Aβ responsible for the increased neurogenesis
[10], inducing an increase in DCX. The ﬁnal outcome would
bethepossibilityofmodulatingadultneurogenesisintheAD
brain by controlling BACE1 activity.
It is safe to predict that the observed increase in
cell proliferation and neuronal diﬀerentiation in these AD
animal models should result in an excess of neurons in the
hippocampus. However, we did not detect morphological
changes in cell number or tissue architecture in these mice.
We postulate that there is an increase of newborn neurons
in Tg-19959 mice; however, probably due to the lack of
trophic factors or not reaching proper targets, most of theseInternational Journal of Alzheimer’s Disease 9
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Figure 7: Eﬀects of siLNA for BACE1, BACE1-AS, and overlap region in neurogenesis markers in vivo. The infusion of siLNA during two
weeks in vivo increased the levels of the neuronal progenitor marker doublecortin (DCX) in both the mRNA (a) and protein (b, duplicates)
level.
newbornneuronswillprobablydiebeforereachingmaturity.
In our previous publication using J20 mice [11] we showed
an increased neurogenesis (measured by Ki67 and BrdU)
in younger animals and a decrease in older mice. We also
describe that most of the newborn neurons died in one
month, before reaching full maturity. We also speculate that
it is possible that the overstimulation of NSC in early ages
could have a negative eﬀect in the NSC pool and neuronal
turnover at older ages, contributing to a higher memory
decline in olderanimals,aswesuggestedin apreviousreview
[30]. The reason why we did not detect an increase in cell
death in the mice is because the amount of newborn cells
proliferation/death is very low versus the total number of
cells, and a moderate increase in cell death could remain
undetected.TheﬁnaloutcomeoftheAβ-drivenneurogenesis
would not be a higher number of working neurons with
Aβ production, quite the contrary, but we believe that the
neurogenic response to Aβ and its manipulation can have a
very important diagnostic value, because we could consider
it the ﬁrst symptom of AD, before cognitive impairment,
cell death, and plaque formation, and the study of its
mechanisms could be very useful in the development of new
approaches in AD diagnostic and prevention.
3.MaterialsandMethods
3.1. Animal Surgeries. siLNAs were designed for mouse
Bace1, Bace1-antisense, and overlapping region between two
transcripts.
We selected 20 mice 8–12 weeks old, 5 animals per group
for surgeries. We inserted cannula into the lateral ventricle
of mice brain and connected the exit port to an Alzet micro
osmotic pump model 1002. We prepared 100nM of each
siLNA, ﬁlled the micro pump, and infused it to the lateral
ventricle of mouse brain, at rate of 0.25μL per hour over
a period of two weeks. Animals were sacriﬁced afterward
and brain was extracted. Five brain regions were separated
from each animal including cerebellum, prefrontal cortex,
striatum, ventral hippocampus, and dorsal hippocampus.
RNAs were isolated by TRIzol, and passed through RNeasy
minicolumn (Qiagen) for on-column DNAse treatment.
We made cDNA, using 400ng of total RNA and random
hexamers, followed by realtime PCR to assess the expression
levels of target RNAs. Relative quantities were measured by
normalizing ct values to β-Actin ct value.
3.2. Animal Studies. Experiments were performed following
National Institute of Health guidelines and approved by The
Animal Care and Use Committee (IACUC) at The Scripps
Research Institute, Scripps, Florida. We are grateful to Dr.
Leissring (Mayo Clinic) for providing APP transgenic (Tg-
19959) mice, a model of AD that overexpresses a doubly
mutated human APP [28]. We used Tg-19959 plus age- and
sex-matched wild type littermates, at diﬀerent ages for the in
vivo experiments. The mice were sacriﬁced in CO2 chamber
followed by decapitation, and the brains were removed.
Five tissues were dissected from each hemibrain; dorsal
hippocampus, ventral hippocampus, cortex, dorsal striatum,
and cerebellum and the other hemibrain were dissected for
RNA and protein studies. The ﬁrst hemibrain was ﬁxed
by immersion in 4% paraformaldehyde for 24 hours and
washed several times in PBS for histology studies.
3.3. RNA Extraction and RT-PCR of the Mouse Brain
Samples. We extracted RNA from dorsal hippocampus, ven-
tral hippocampus, cortex, dorsal striatum, and cerebellum
from each mouse brain, using Trizol reagent (Invitrogen),
according to the manufacturer’s protocol. RNA samples
were passed through Qiagen RNeasy columns and were
subjected to on-column DNAse treatment for removal of
DNA contamination. We used 800ng of each RNA sample
for the ﬁrst strand cDNA synthesis and carried out RT-PCR
measurements. We plotted the percentile changes in RNA
levels, for individual tissues compared to control mice, in
each graph.10 International Journal of Alzheimer’s Disease
3.4. Realtime PCR (RT-PCR). We carried out RT-PCR with
the GeneAmp 7900 machine (Applied Biosystems). The PCR
reactions contained 20–40ng cDNA, Universal Mastermix,
300nM of forward and reverse primers, and 200nM of
probe in a ﬁnal reaction volume of 15μL. We designed
the primers and probe using FileBuilder software (Applied
Biosystems). They were strand-speciﬁc for sense-antisense
pairs and the sense probes covered exon boundaries to
eliminate the chance of genomic DNA ampliﬁcation. The
PCR conditions for all genes were as follows: 50◦Cf o r2m i n
then 95◦C for 10min then 40 cycles of 95◦Cf o r1 5 sa n d
60◦C for 1min. The results are based on cycle threshold (Ct)
values. We calculated diﬀerences between the Ct values for
experimental and reference genes (18s RNA) as ΔΔCt and
graphed as a percent of each RNA to the calibrator sample.
3.5. Western Blotting and ELISA. Brain tissues were homog-
enized in Tissue Extraction Reagent I (Biosource) containing
protease inhibitor cocktail complete Mini (Roche) by 20 up-
and-down passes in a glass Dounce homogenizer. Samples
were centrifuged at 14,000rpm for 30min. Supernatants
were used for ELISA quantiﬁcation using an Aβ 1–40 and
1–42 AlphaLISA amyloid kit (PerkinElmer) and quantiﬁed
with ENVISION 2104 Multilabel reader (PerkinElmer).
Same supernatants were used for Western blot detection
using mouse 4G8 antibody anti-Aβ (Signet), mouse Rat-401
anti-nestin (Developmental Studies Hybridoma Bank), and
Rabbit anti-doublecortin (cell signaling).
3.6. Guanidine Extraction of Insoluble A-Beta Species. 200μL
of 6.25M Guanidine-HCl (Sigma-Aldrich, MO) in 50mM
Tris at pH 8 was added to the pellet. The mixture was
vortexed vigorously for 5 minutes until the pellet was
fully dissolved. The solution was incubated overnight at
room temperature. The following day, the mixture was
centrifuged at 14,000g for 10 minutes, and the supernatant
collected into fresh tubes and labeled as Guanidine extracted
(insoluble) fraction. Protein quantiﬁcation and Aβ ELISA
was performed as for the soluble fraction.
3.7. Immunohistochemistry. One hemibrain was ﬁxed in
phosphate-buﬀered 4% paraformaldehyde, pH 7.4, at 4◦C
for24hr,washedinphosphatebuﬀerthreetimesandembed-
ded in 3% agarose for vibratome sectioning (Micron HM
650V. Thermo Scientiﬁc). 50μm sections of hemibrain were
made in the sagittal axis. Sections were permeabilized in PBS
with 1% TX-100 and maintained in this solution with 10%
FCS with primary antibodies for two days with agitation.
As a negative control, adjacent brain slices were similarly
processed, except that the primary antibody was omitted.
Rabbit anti Ki67 (Vector) and mouse 4G8 antibody anti-Aβ
(Signet). Immunoﬂuorescence secondary goat anti mouse or
goat anti-rabbit Alexa Fluor 568 and 488 antibodies were
used for detection.
4. Conclusions
We examined the pattern of neurogenesis in a transgenic
mouse model of AD (Tg-19959) and found increased
neurogenesis compared to age-matched wild type mice at
all ages examined. This increase in neurogenesis occurs very
early in the development of the disease, and is paralleled by
an accumulation of Aβ oligomeric species. LNA-modiﬁed
siRNAs targeting BACE1, BACE1-AS, or both transcripts
reduced BACE1 at the mRNA and protein level, reduced the
levels of insoluble Aβ peptides, and changed the aggregation
patternofsolubleAβinthebrainofTg-19959mice.Ourdata
suggest that the increased neurogenesis observed in a mouse
model of AD parallels the accumulation of oligomeric Aβ
species and that we can manipulate it by using with LNA-
modiﬁed siRNAs against BACE1 and BACE1-AS. We believe
thatthestudyof Aβ-driven neurogenesis couldbe a powerful
tool in early detection of AD, and the use of ncRNAs could
help to manipulate the development of the disease before the
appearance of adverse symptoms.
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